333 related articles for article (PubMed ID: 11801676)
1. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice.
Cretney E; Takeda K; Yagita H; Glaccum M; Peschon JJ; Smyth MJ
J Immunol; 2002 Feb; 168(3):1356-61. PubMed ID: 11801676
[TBL] [Abstract][Full Text] [Related]
2. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
Takeda K; Smyth MJ; Cretney E; Hayakawa Y; Yamaguchi N; Yagita H; Okumura K
Cell Immunol; 2001 Dec; 214(2):194-200. PubMed ID: 12088418
[TBL] [Abstract][Full Text] [Related]
3. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
Giovarelli M; Musiani P; Garotta G; Ebner R; Di Carlo E; Kim Y; Cappello P; Rigamonti L; Bernabei P; Novelli F; Modesti A; Coletti A; Ferrie AK; Lollini PL; Ruben S; Salcedo T; Forni G
J Immunol; 1999 Nov; 163(9):4886-93. PubMed ID: 10528190
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.
Smyth MJ; Cretney E; Takeda K; Wiltrout RH; Sedger LM; Kayagaki N; Yagita H; Okumura K
J Exp Med; 2001 Mar; 193(6):661-70. PubMed ID: 11257133
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.
Seki N; Hayakawa Y; Brooks AD; Wine J; Wiltrout RH; Yagita H; Tanner JE; Smyth MJ; Sayers TJ
Cancer Res; 2003 Jan; 63(1):207-13. PubMed ID: 12517799
[TBL] [Abstract][Full Text] [Related]
6. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development.
Takeda K; Smyth MJ; Cretney E; Hayakawa Y; Kayagaki N; Yagita H; Okumura K
J Exp Med; 2002 Jan; 195(2):161-9. PubMed ID: 11805143
[TBL] [Abstract][Full Text] [Related]
7. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells.
Takeda K; Hayakawa Y; Smyth MJ; Kayagaki N; Yamaguchi N; Kakuta S; Iwakura Y; Yagita H; Okumura K
Nat Med; 2001 Jan; 7(1):94-100. PubMed ID: 11135622
[TBL] [Abstract][Full Text] [Related]
8. TRAIL: a mechanism of tumor surveillance in an immune privileged site.
Lee HO; Herndon JM; Barreiro R; Griffith TS; Ferguson TA
J Immunol; 2002 Nov; 169(9):4739-44. PubMed ID: 12391182
[TBL] [Abstract][Full Text] [Related]
9. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy.
Hayakawa Y; Screpanti V; Yagita H; Grandien A; Ljunggren HG; Smyth MJ; Chambers BJ
J Immunol; 2004 Jan; 172(1):123-9. PubMed ID: 14688317
[TBL] [Abstract][Full Text] [Related]
10. Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein.
Wu X; He Y; Falo LD; Hui KM; Huang L
Mol Ther; 2001 Mar; 3(3):368-74. PubMed ID: 11273779
[TBL] [Abstract][Full Text] [Related]
11. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells.
Kayagaki N; Yamaguchi N; Nakayama M; Takeda K; Akiba H; Tsutsui H; Okamura H; Nakanishi K; Okumura K; Yagita H
J Immunol; 1999 Aug; 163(4):1906-13. PubMed ID: 10438925
[TBL] [Abstract][Full Text] [Related]
12. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye.
Wang S; Boonman ZF; Li HC; He Y; Jager MJ; Toes RE; Niederkorn JY
J Immunol; 2003 Sep; 171(6):2789-96. PubMed ID: 12960299
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
14. Reduced apoptosis and ameliorated listeriosis in TRAIL-null mice.
Zheng SJ; Jiang J; Shen H; Chen YH
J Immunol; 2004 Nov; 173(9):5652-8. PubMed ID: 15494516
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL).
Routes JM; Ryan S; Clase A; Miura T; Kuhl A; Potter TA; Cook JL
J Immunol; 2000 Oct; 165(8):4522-7. PubMed ID: 11035092
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of the expression of CD95 ligand, receptor activator of nuclear factor-kappa B ligand (RANKL), TNF-related apoptosis-inducing ligand (TRAIL), and TNF-alpha during T cell activation.
Wang R; Zhang L; Zhang X; Moreno J; Luo X; Tondravi M; Shi Y
J Immunol; 2001 Feb; 166(3):1983-90. PubMed ID: 11160247
[TBL] [Abstract][Full Text] [Related]
17. [Current advances and expectations in tumor immunology].
Takeda K; Okumura K
Hum Cell; 2001 Sep; 14(3):159-63. PubMed ID: 11774735
[TBL] [Abstract][Full Text] [Related]
18. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.
Ostrand-Rosenberg S; Grusby MJ; Clements VK
J Immunol; 2000 Dec; 165(11):6015-9. PubMed ID: 11086031
[TBL] [Abstract][Full Text] [Related]
19. TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality.
Corazza N; Jakob S; Schaer C; Frese S; Keogh A; Stroka D; Kassahn D; Torgler R; Mueller C; Schneider P; Brunner T
J Clin Invest; 2006 Sep; 116(9):2493-9. PubMed ID: 16955144
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity.
Dorothée G; Vergnon I; Menez J; Echchakir H; Grunenwald D; Kubin M; Chouaib S; Mami-Chouaib F
J Immunol; 2002 Jul; 169(2):809-17. PubMed ID: 12097384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
